You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. ICU-CARE: An interactive mobile app to enhance the efficiency of daily informal caregiving in the intensive care unit

    SBC: SILICON CURES LLC            Topic: NINR

    PROJECT SUMMARY Actively involving informal caregivers in direct patient care at the bedside in the intensive care unit (ICU) has the potential to improve patient, informal caregiver, and health care system outcomes. Practice guidelines call for the liberal inclusion of informal caregivers as active partners in ICU care, but there is a critical, unmet need to develop tools that effectively operati ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Implementation and validation of a lung x-ray interferometry imaging system, with applications to COPD, COVID-19 and other lung diseases

    SBC: REFINED IMAGING, LLC            Topic: NHLBI

    AbstractLung diseases ranging from cancer to chronic obstructive pulmonary disease (COPD) affect large numbers of men and women worldwide each year. Current news reports describe the respiratory impact of COVID-19; likewise, the past year has seen extensive coverage of the respiratory problems caused by vaping. Worldwide, lung diseases of all types result in millions of deaths per year at a stagge ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Chemosensitization of Glioblastoma by Propentofylline

    SBC: Oleolive, Inc.            Topic: 102

    SUMMARY Glioblastoma (GBM) is the most common primary tumor of the CNS with limited treatment options and a poor clinical prognosis. Standard of care treatment, including surgical resection, radiation therapy and concurrent temozolomide (TMZ) treatment followed by adjuvant TMZ, produces a median survival in newly diagnosed GBM of ~15 months. Tumor recurrence happens due to therapy resistant tumor ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. New anti-glioblastoma metabolic compounds with high potential for Blood Brain Barrier penetration

    SBC: WAYPATH PHARMA LLC            Topic: NCI

    Glioblastomas are very aggressive tumors of the central nervous system (CNS) with a median patient survival of about 16 months. Therapeutic options for glioblastoma patients are very limited mostly because the majority of potential anti-cancer drugs do not cross the blood brain barrier (BBB). In addition, recently tested immunotherapies including immune checkpoint inhibitors, tumor vaccines, and a ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. The re-activatable Yb-169 radiation source: a therapeutic medical device to reduce the risk of brachytherapy and increase adoption

    SBC: PXALPHA, L.L.C.            Topic: NCI

    PROJECT SUMMARY/ABSTRACT: There is currently a technological gap in high-dose-rate brachytherapy (HDR-BT) that has stunted the efficacy of single-fraction HDR-BT monotherapy for prostate cancer patients and is preventing a shift away from invasive interstitial brachytherapy to an intracavitary-only approach for cervical cancer patients. The gap is due to the radiation dose conformity limitations o ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Efficacy of an Electrophile Scavenger in the Prevention of Gastrointestinal Inflammatory Carcinogenesis

    SBC: MTI Biotech Incorporated            Topic: 102

    SUMMARY: Many cancers are recognized to have an inflammatory etiology. Gastric cancer, the third leading cause of cancer deaths worldwide, is the prototype- it is caused by infection with the bacterial pathogen Helicobacter pylori in 90% of cases. For colorectal cancer (CRC), the second leading cause of cancer deaths, inflammatory bowel disease (IBD) is a frequent precursor lesion. This STTR Phase ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. 2-HOBA for Treatment of Pulmonary Hypertension

    SBC: MTI Biotech Incorporated            Topic: NHLBI

    PROJECT SUMMARY Although the ubiquity of metabolic problems in pulmonary hypertension (PH) has been known for more than a decade, a wealth of new details on the nature of this problem presents the opportunity for intervention. A combination of experimental work in cells and animals and early trials in humans, suggests that these metabolic problems are part of the causation for PH, and that inactiv ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Targeted Radiotherapeuitc for Pancreatic Ductal Adenocarcinoma

    SBC: ADDUCTNE LLC            Topic: 102

    In 2020 alone, pancreatic cancer is estimated to have resulted in 47,050 deaths in the U.S. making it the fourth leading cause of cancer-related death. Pancreatic ductal adenocarcinoma (PDAC) makes up greater than 90% of all pancreatic cancer diagnoses and has an overall five-year survival rate of just 10%. New therapeutic options are needed to improve the poor prognosis for patients with PDAC. Ex ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Evaluation of In Vivo Efficacy of a Novel Microbial Therapy to Treat Cognitive Deficits in Alzheimers disease

    SBC: PROBIOME THERAPEUTICS, INC.            Topic: NIA

    PROJECT SUMMARY/ABSTRACT Alzheimer’s disease (AD) is a leading cause of dementia, yet no effective therapeutic intervention is available for those in prodromal and early stages of AD. Restoration of functional and cognitive resilience in early disease stages is especially beneficial in many aspects as it could substantially extend the period of quality of life and delay the clinical onset of AD. ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. PHMB-Impregnated Acellular Biologic Grafts for Treatment of Third-Degree Burns

    SBC: BioAesthetics Corporation            Topic: 300

    PROJECT SUMMARY BioAesthetics is developing a novel acellular graft for improved burn wound healing. Our patent- pending drug-loaded, polymer-integrated acellular biologic graft (PCT/US19/25306) will act as a barrier to pathogens, deliver anti-infectives to the wound site during healing, and provide an optimal regenerative scaffold. This will allow for a single-stage wound reconstruction, without ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government